TOLPERISONE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H23NO.ClH
Molecular Weight	281.821
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CC(CN1CCCCC1)C(=O)C2=CC=C(C)C=C2

InChI

InChIKey=ZBUVYROEHQQAKL-UHFFFAOYSA-N

InChI=1S/C16H23NO.ClH/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17;/h6-9,14H,3-5,10-12H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	C16H23NO
Molecular Weight	245.3599
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Tolperisone_31/WC500141050.pdf
Curator's Comment: description was created based on several sources, including https://pharmacybook.net/mydocalm/ | http://en.remedy-info.com/ovr0_midokalm.html | https://www.ncbi.nlm.nih.gov/pubmed/18482024 | https://www.ncbi.nlm.nih.gov/pubmed/232053

Tolperisone is a centrally acting muscle relaxant first synthesized in 1956 and used in clinical practice since the 1960’s. Tolperisone is an aryl alkyl β-aminoketone with an asymmetric carbon atom α to the carbonyl group. The dextrorotatory enantiomer was reported less effective, however, no detailed analyses of the enantiomers are available. The precise mechanism of action of tolperisone is not fully known. The most prominent effect of tolperisone is its inhibitory action on pathways of spinal reflexes. It suppresses the mono and polysynaptic reflex transmission by both pre-synaptic and post-synaptic mechanisms.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium channel alpha subunit 72 Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16126840	Inhibitor 8504		198.0 µM [IC50]
Voltage-gated calcium channel 37 Target ID: CHEMBL2363032 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16126840	Inhibitor 8504		1062.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Muscle hypertonia 3 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18482024	Primary		Approved 8583	Mydocalm Approved Use Unknown

C_max

Value	Dose	Analyte	Population
297.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16681042/	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
64.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23217307/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
90.88 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
229.47 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
54 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
98.85 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
205.2 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
70.89 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
115.44 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
516 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16681042/	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
111.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23217307/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
151.92 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
682.03 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
81.09 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
170.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
274.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
101.11 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
194.63 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
1.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16681042/	450 mg single, oral dose: 450 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
3.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23217307/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.66 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.33 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.84 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.44 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25953735/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:	TOLPERISONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
900 mg 3 times / day multiple, oral Highest studied dose Dose: 900 mg, 3 times / day Route: oral Route: multiple Dose: 900 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15885050/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/15885050/	Sources: https://pubmed.ncbi.nlm.nih.gov/15885050/
15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	Other AEs: Apnoea, Myoclonus... Other AEs: Apnoea Myoclonus Tachycardia Hypotension Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
25 mg single, oral Studied dose Dose: 25 mg Route: oral Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21905508/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21905508/	Other AEs: Urticaria, Anxiety... Other AEs: Urticaria Anxiety Sources: https://pubmed.ncbi.nlm.nih.gov/21905508/
2700 mg single, oral Accidental dose Dose: 2700 mg Route: oral Route: single Dose: 2700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	healthy, CHILD Health Status: healthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	Other AEs: Seizures, Apnoea... Other AEs: Seizures Apnoea Cardiac arrest Acidosis (grade 3) Hypokalaemia Brain hypoxia Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/

AEs

AE	Significance	Dose	Population
Apnoea		15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Hypotension		15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Myoclonus		15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Tachycardia		15000 mg single, oral Overdose Dose: 15000 mg Route: oral Route: single Dose: 15000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	unknown, ADULT Health Status: unknown Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Anxiety		25 mg single, oral Studied dose Dose: 25 mg Route: oral Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21905508/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21905508/
Urticaria		25 mg single, oral Studied dose Dose: 25 mg Route: oral Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/21905508/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/21905508/
Apnoea		2700 mg single, oral Accidental dose Dose: 2700 mg Route: oral Route: single Dose: 2700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	healthy, CHILD Health Status: healthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Brain hypoxia		2700 mg single, oral Accidental dose Dose: 2700 mg Route: oral Route: single Dose: 2700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	healthy, CHILD Health Status: healthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Cardiac arrest		2700 mg single, oral Accidental dose Dose: 2700 mg Route: oral Route: single Dose: 2700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	healthy, CHILD Health Status: healthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Hypokalaemia		2700 mg single, oral Accidental dose Dose: 2700 mg Route: oral Route: single Dose: 2700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	healthy, CHILD Health Status: healthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Seizures		2700 mg single, oral Accidental dose Dose: 2700 mg Route: oral Route: single Dose: 2700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	healthy, CHILD Health Status: healthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/
Acidosis	grade 3	2700 mg single, oral Accidental dose Dose: 2700 mg Route: oral Route: single Dose: 2700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/	healthy, CHILD Health Status: healthy Age Group: CHILD Sex: unknown Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25772423/

PubMed

Title	Date	PubMed
Comparative study of therapeutic response to baclofen vs tolperisone in spasticity.	2017-03	28086137
Pharmacological interventions other than botulinum toxin for spasticity after stroke.	2016-10-06	27711973
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011-07-14	21599003
Differential effects of painful and non-painful stimulation on tactile processing in fibromyalgia syndrome and subjects with masochistic behaviour.	2010-12-28	21203391
Classification of drugs based on properties of sodium channel inhibition: a comparative automated patch-clamp study.	2010-12-20	21187965
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010-12	21818443
[IGOST guideline for pharmacotherapy of low back pain].	2010-08-12	20828068
Tolperisone.	2010-02	20653161
NMR analysis, protonation equilibria and decomposition kinetics of tolperisone.	2009-12-05	19577875
[Co-analgesics--today and tomorrow--a receptor-based overview of therapeutical options].	2009-11	19918705
[New therapies for spastic movement disorders].	2009-10	20623938
[Efficiency local injection therapy with preparation mydocalm in myofascial pain syndrome cervicobrachial region].	2009	19688873
Cannabinoids in the management of spasticity associated with multiple sclerosis.	2008-10	19183777
[Comparative efficacy of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].	2008	18833102
Tolperisone: a typical representative of a class of centrally acting muscle relaxants with less sedative side effects.	2008	18482024
Determination of eperisone in human plasma by liquid chromatography-ESI-tandem mass spectrometry.	2007-09	17958338
Considerable interindividual variation in the pharmacokinetics of tolperisone HCl.	2007-02	17323790
Silperisone: a centrally acting muscle relaxant.	2007-01-18	17227288
Grand rounds: an outbreak of toxic hepatitis among industrial waste disposal workers.	2007-01	17366828
[Use of local injections of tolperisone (midocalm) in combination with tractional therapy in the treatment of vertebral static syndrome].	2007	18379519
[Post-operative pain therapy of a chronic pain patient].	2006-11	17151986
[Comparative effciency of bakloferon and tolperizon central muscle relaxants in complex therapy of back pain].	2006-09	17180860
A comparative study of the action of tolperisone on seven different voltage dependent sodium channel isoforms.	2006-05-24	16650844
HPLC determination of tolperisone in human plasma.	2006-04	16681042
[A randomized, double blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke].	2006	16457132
Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels.	2005-12	16126840
A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke.	2005-06	15885050
[A study of mydocalm efficiency in the treatment of chronic headache of tension].	2005	16450434
[Midocalm in complex therapy of chronic low back pain syndrome].	2005	16404939
Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms.	2004-11-07	15530171
Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.	2004-10-18	16125625
Antinociceptive effects of sodium channel-blocking agents on acute pain in mice.	2004-06	15215642
[Restorative treatment of degenerative-dystrophic diseases of large joints].	2004	15199782
Separation of basic drug enantiomers by capillary electrophoresis using chicken alpha1-acid glycoprotein: insight into chiral recognition mechanism.	2003-08	12900854
Anaphylactic reactions to tolperisone (Mydocalm).	2003-06-28	12947534
[Back aches often become a chronic problem. Sodium channel block against chronification].	2003-06-19	12891859
[Fibromyalgia also has psychological origins. "Often harmony seeking perfectionists"].	2003-05-01	12838908
Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.	2003-05	12695352
Simultaneous micellar LC determination of lidocaine and tolperisone.	2003-03-26	12644189
[To make easier everyday life of stroke patients. Muscle relaxants diminish spasms].	2003-02-27	12666538
[Mydocalm causing anaphylaxis].	2003	14587432
Effect of muscle relaxants on experimental jaw-muscle pain and jaw-stretch reflexes: a double-blind and placebo-controlled trial.	2003	12935797
Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force--a double-blind randomized crossover control study.	2003	12935792
[Spinal pain and its treatment with midocalm].	2003	12847906
[Patient with chronic backache. Disabled or muscle spasm patient?].	2002-12-05	12577750
[Muscular pain and fatigue: is fibromyalgia sticking behind? These points bring it to light].	2002-10-31	12494602
Protein domain of chicken alpha(1)-acid glycoprotein is responsible for chiral recognition.	2002-07-19	12099678
[Preventing chronification. So pain isn't branded into memory].	2002-05-16	12119891
[Mydeton: a centrally acting muscle relaxant drug from Gedeon Richter LTD].	2002	12426787
[Neuropharmacological studies on tolperisone hydrochloride (author's transl)].	1979-10	232053

Patents

Sample Use Guides

In Vivo Use Guide

The usual dose is Mydocalm (tolperisone) 150 mg, 1-3 times a day. It should be taken after meal. The maximum daily dose is 450 mg

Route of Administration: Oral

In Vitro Use Guide

The sodium channel blocking effects of Tolperisone was characterized in electrophysiological experiments on dorsal root ganglion (DRG) cells. DRG cells were acutely dissociated from rat DRG of 6-day-old male rats. Tolperisone (0, 40, 80, 160, 320, and 640 mkM) dissolved in the extracellular solution were applied onto the cells via multibarreled ejection pipettes controlled by electromagnetic valves. Currents were recorded from fast-kinetics tetrodotoxin-sensitive DRG cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:32:56 GMT 2025` Edited by `admin` on `Mon Mar 31 17:32:56 GMT 2025`
Record UNII	8Z075K2TIG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ABBSA

Preferred Name

English

TOLPERISONE HYDROCHLORIDE

Common Name

English

TOLPERISONE HYDROCHLORIDE [MI]

Common Name

English

MIDOCALM

Brand Name

English

1-PROPANONE, 2-METHYL-1-(4-METHYLPHENYL)-3-(1-PIPERIDINYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

MINACALM

Brand Name

English

ARANTOICK

Brand Name

English

2,4'-DIMETHYL-3-PIPERIDINOPROPIOPHENONE HYDROCHLORIDE

Systematic Name

English

NAISMERITIN

Brand Name

English

TOLFREE

Brand Name

English

TOLPERISONE HYDROCHLORIDE [MART.]

Common Name

English

BIOCALM

Brand Name

English

BESNOLINE

Brand Name

English

KINEORL

Brand Name

English

ISOCALM

Brand Name

English

Tolperisone hydrochloride [WHO-DD]

Common Name

English

TOLPERISONE HCL

Common Name

English

N-553

Code

English

ATMOSGEN

Brand Name

English

TOLPIDOL

Brand Name

English

METOSOMIN

Brand Name

English

MUSCALM

Brand Name

English

MENOPATOL

Brand Name

English

2-METHYL-3-PIPERIDINO-1-P-TOLYLPROPAN-1-ONE HYDROCHLORIDE

Common Name

English

TOLPERISONE HYDROCHLORIDE [JAN]

Common Name

English

1-PIPERIDINO-2-METHYL-3-(P-TOLYL)-3-PROPANONE HYDROCHLORIDE

Common Name

English

MYDOCALM

Brand Name

English

TOLISARTINE

Brand Name

English

2-METHYL-1-(4-METHYLPHENYL)-3-(1-PIPERIDINYL)-1-PROPANONE HYDROCHLORIDE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29696